Antibody-Drug Conjugate Coverage
Customize your policy alerts
Sign up for Premera Bluecross Policy 5.01.582 alerts
Get alerted when Policy 5.01.582 changes without checking for updates manually.
Monitor payer policy activity
Medical-necessity coverage and prior authorization for specified antibody-drug conjugates used to treat hematologic and solid malignancies under the medical benefit.
Updated Padcev criteria to include combination therapy with pembrolizumab and berahyaluronidase alfa-pmph for locally advanced or metastatic urothelial cancer.
Removed the requirement that individuals receiving Padcev for muscle-invasive bladder cancer be ineligible for cisplatin-containing chemotherapy.
Added Datroway coverage criteria for triple-negative breast cancer.
Added Datroway coverage criteria for locally advanced or metastatic EGFR-mutated non-small-cell lung cancer.
Added Emrelis coverage criteria for locally advanced or metastatic non-squamous non-small-cell lung cancer with high c-Met protein overexpression.
Added coverage criteria for Datroway.
Moved Adcetris and Polivy from policy 2.03.502 to this antibody-drug conjugate policy.
Updated Besponsa age eligibility from 18 years to 1 year or older.
Expanded Mylotarg coverage for newly diagnosed CD33-positive acute myeloid leukemia.
Added Zynlonta for relapsed or refractory large B-cell lymphoma.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.